Qiagen stock steadies as investors await fresh numbers

Qiagen (NL0012169213) is trading against a backdrop of reported 2025 revenue of EUR 1.99 billion and adjusted diluted EPS of EUR 2.16, two figures that frame the stock even without a fresh catalyst in the search results. The company also reported net sales growth of 7% in constant exchange rates for 2025, which gives investors a dated operating reference point for the shares.

EUR 1.99 billion sets the base

Qiagen said full-year 2025 net sales reached EUR 1.99 billion, up 7% at constant exchange rates, while adjusted diluted EPS came to EUR 2.16. Those figures matter because they define the last full-year earnings base before the next reporting cycle and show that the company entered 2026 with a higher revenue level than the prior year.

The same 2025 comparison also points to margin discipline, because adjusted diluted EPS of EUR 2.16 must be read alongside the revenue increase rather than in isolation. For a life-science tools company, that mix of top-line growth and earnings progression is often what investors use to judge whether demand held up across the portfolio.

Growth was 7% in constant currency

The 7% constant-currency sales increase in 2025 is the key comparison point. It is a concrete year-over-year reference that helps separate reported growth from currency effects and gives the share story more substance than a simple revenue total would on its own.

Qiagen also remains a company tied to recurring demand in sample and assay workflows, so the next quarterly update will matter less for one headline number than for the continuation of that 2025 trend. The market typically watches whether that 7% pace can be defended while earnings per share continue to improve.

Q1 2025 adds another marker

In the first quarter of 2025, Qiagen reported net sales of USD 483 million and adjusted diluted EPS of USD 0.51. That quarter provides a second dated operating marker and shows how the company performed earlier in the year before the full-year 2025 result was published.

Those two numbers also give a useful comparison frame: Q1 2025 sales of USD 483 million sit inside the wider 2025 revenue base of EUR 1.99 billion, while EPS of USD 0.51 shows the quarterly earnings level that later fed into the full-year adjusted EPS figure of EUR 2.16. The combination is more informative than a single report line.

QIAGEN products remain central

A representative product line for Qiagen is its QIAstat-Dx molecular diagnostics platform, which sits in the companys broader sample technologies and diagnostics mix. The product matters because platform-level demand helps explain why the company can post revenue and EPS figures that investors continue to benchmark quarter by quarter.

That kind of product exposure is also why the 2025 net sales figure of EUR 1.99 billion is more than a static annual number. It reflects the commercial traction of consumables, instruments, and diagnostics workflows across a year of shifting laboratory demand.

Market value stays measurable

Because the search results for this call did not include a verified live quote page, the cleanest dated market anchor is the reported 2025 earnings base rather than a live trading print. Qiagen stock therefore reads today as a numbers story centered on EUR 1.99 billion in 2025 revenue, 7% constant-currency growth, and adjusted diluted EPS of EUR 2.16.

For investors tracking the name, those are the figures that define the starting point until the next dated release provides a new market reference.